SEMA3A and neoplasm: After multiple failed clinical trials, research shifted from an anti-angiogenic approach to tumor vessel normalization though the blocking of the VEGF–VEGFR2 axis with Semaphorin 3A (SEMA3A) which targets nucleolin [182].